US-LISTED clinical-stage biopharmaceutical company Corvus has entered into an agreement with Monash University giving it rights to a product developed in Monash's novel immuno-oncology program.
Corvus said it targets the adenosine receptor pathway and this arrangement has the potential to bolster drug development both within and without that pathway.
Monash's Professor Charles MacKay and Dr Remy Robert "have created a first-class asset for the treatment of cancer," said Monash Biomedicine Discovery Institute director Professor John Carroll.
The above article was sent to subscribers in Pharmacy Daily's issue from 11 May 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 May 17